Title |
JAK3-STAT pathway blocking benefits in experimental lupus nephritis
|
---|---|
Published in |
Arthritis Research & Therapy, June 2016
|
DOI | 10.1186/s13075-016-1034-x |
Pubmed ID | |
Authors |
Èlia Ripoll, Laura de Ramon, Juliana Draibe, Ana Merino, Nuria Bolaños, Montse Goma, Josep M. Cruzado, Josep M. Grinyó, Juan Torras |
Abstract |
Lupus nephritis (LN) is a complex chronic autoimmune disease of unknown etiology characterized by loss of tolerance against several self-antigens. Cytokines are known to be central players in LN pathogenesis. The Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is one important pathway that mediates signal transduction of several cytokines. In this study, we examined the pathogenic role of this pathway and how CP-690,550 treatment influences LN outcome. Six-month-old NZB/NZWF1 mice were divided into two different treatment groups: (1) control animals given vehicle treatment, cyclophosphamide, and mycophenolate mofetil treatment as positive controls of the therapy and (2) mice treated with CP-690,550, a JAK3 inhibitor. Mice were treated for 12 weeks. We evaluated renal function, anti-double-stranded DNA (anti-dsDNA) antibody, renal histology changes, kidney complement and immunoglobulin G (IgG) deposits, T-cell and macrophage infiltration, kidney inflammatory gene expression, and circulating cytokine changes. CP-690,550 treatment significantly reduced proteinuria and improved renal function and histological lesions of the kidney. Compared with vehicle-treated animals, those undergoing CP-690,550 treatment showed significantly diminished anti-dsDNA antibody and complement component C3 and IgG deposition in glomeruli. We also observed a significant reduction of T-cell and macrophage infiltration. Kidney gene expression revealed a reduction in inflammatory cytokines and complement and related macrophage-attracting genes. Circulating inflammatory cytokines were also reduced with treatment. On the basis of our results, we conclude that the JAK-STAT pathway is implicated in the progression of renal inflammation in NZB/WF1 mice and that targeting JAK3 with CP-690,550 is effective in slowing down the course of experimental LN. Thus, CP-690,550 could become a new therapeutic tool in LN and other autoimmune diseases. |
Twitter Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Singapore | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 48 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 12 | 25% |
Student > Master | 8 | 17% |
Other | 5 | 10% |
Student > Bachelor | 4 | 8% |
Researcher | 4 | 8% |
Other | 5 | 10% |
Unknown | 10 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 13 | 27% |
Biochemistry, Genetics and Molecular Biology | 6 | 13% |
Immunology and Microbiology | 5 | 10% |
Agricultural and Biological Sciences | 3 | 6% |
Unspecified | 3 | 6% |
Other | 8 | 17% |
Unknown | 10 | 21% |